Georgia Life Sciences Designates City of Atlanta as Newest BioReady® Community
Georgia Life Sciences Designates City of Atlanta as Newest BioReady® Community
ATLANTA – February 20, 2025- Today, Invest Atlanta announced, the city of Atlanta has been designated a BioReady Gold Community by the state’s leading life sciences membership organization, Georgia Life Sciences. To receive this distinction, communities must meet certain criteria related to zoning practices and infrastructure capacity. This distinctive honor was presented today during Invest Atlanta’s February board of directors meeting.
“We are proud to recognize the City of Atlanta as a BioReady site, as much of our life sciences ecosystem is built around the state’s capital city,” said Maria Thacker-Goethe, President and CEO of Georgia Life Sciences. “Through this program, we champion communities that have made a commitment to growing the life sciences industry, helping to distinguish the state with not only a significant presence of leading biopharma companies and startups, but also with robust funding opportunities to fuel growth, and a collaborative environment with access to resources and infrastructure.”
The BioReady rating system rates communities in three tiers from Bronze to Silver to Gold. Through these BioReady ratings, Georgia Life Sciences allows local municipalities to better showcase biotech-zoned science parks, streamline permitting, build a robust infrastructure, and identify biotech-friendly sites more effectively, making them a desirable choice for real estate developers and biotechnology companies seeking destinations to locate.
“We are thrilled to witness our city being recognized as a BioReady Gold Community, a testament to our commitment to innovation and sustainability in the life sciences,” said Atlanta Mayor Andre Dickens. This acknowledgment not only highlights our readiness but also paves the way for future growth and collaboration in the bioscience sector. This designation affirms Atlanta’s readiness to support biotech companies and reinforces our position as a hub for scientific innovation.”
“According to BioSpace, the global life sciences market is valued at $13.72 billion and is projected to reach $26.63 billion by 2033,” said Dr. Eloisa Klementich, president and CEO of Invest Atlanta. Earning BioReady Gold status strengthens our efforts to attract and retain biotech and life sciences companies. With the Life Sciences workforce expected to grow 10% from 2022 to 2032, this recognition reinforces Invest Atlanta’s commitment to biotech and life sciences, giving companies confidence in our support and resources.”
For more information about this recognition visit, BioReady Communities.
About Georgia Life Sciences
Georgia Life Sciences, founded in 1989, is a non-profit, membership-based organization that promotes the interests and growth of the life sciences industry. It is the state’s largest and most influential life sciences advocacy and business leadership organization working to improve access to innovative discoveries that have lifesaving impact. The association connects business, academia, government, and other allied entities involved in the application of life sciences products to fuel growth and collaboration through policy development, community programs, national industry initiatives, and a portfolio of educational and networking events. Learn more at www.galifesciences.org.
Members are invited to join G2G’s Monthly GBG Reporting Service Webinar on September 18, 2025 . The first portion ( 12:00–12:30 PM ET ) is free and open to all, offering a high-level overview of current federal funding trends. The second half ( 12:30–1:00 PM ET ) is a premium consultation available only to Georgia Life Sciences members, offering direct access to G2G’s expert team—who have helped secure over $550 million in non-dilutive government funding since 2007. Register here: https://www.g2gconsulting.com/event/non-dilutive-funding-g2gs-monthly-gbg-reporting-service-webinar-14-3/2025-09-18/ Key opportunities this month include DARPA’s Expedited Research Innovation System for CBRN threat defense technologies, BARDA’s I-CREATE diagnostic funding and VANGUARD biomanufacturing tools development (each offering up to $200,000), NIAID tuberculosis and influenza research units (up to $1.5–$2.5 million annually), DoD’s $4 million Advanced Medical Monitor development through MTEC, and multiple SBIR opportunities for sensors and field-deployable diagnostics (up to $209,575 for Phase I awards). The September GBG report highlights 13 immunology and infectious disease opportunities, 10 cognitive and brain health programs, and several biotechnology and biomanufacturing initiatives across federal agencies including the Army, ARPA-H, BARDA, and NSF. Georgia Life Sciences members can access the complete 29-page report with detailed deadlines and eligibility requirements [insert link or portal instructions here]. GLS members can access the full 29-page report with deadlines and submission details by logging into your member portal.
Protecting U.S. Leadership in Agricultural Biotechnology
Celebrating the Next Generation of Scientific Breakthroughs in Georgia
